Does microdosing psilocybin work? What the studies show
Large surveys find that people who microdose psilocybin report better mood and less anxiety. But when researchers hide who got psilocybin and who got a placebo, most of those differences shrink or disappear, which points to expectation as a big part of the effect. Here's an honest summary of the evidence through 2026.
On this page
- Observational studies
- Microdosers report better mood and lower anxiety and stress than non-users
- Placebo-controlled trials
- Mostly no clear benefit over placebo on mood, creativity or cognition
- Likely explanation
- Expectancy (placebo) effects explain much of the reported benefit
- Open safety question
- Long-term effects of frequent dosing on heart valves (5-HT2B receptors) are not well studied
- Last checked
- October 20, 2026
What microdosing means
Microdosing means taking a small fraction of a full psychedelic dose, small enough to avoid a noticeable trip, often on a repeating schedule. People who microdose psilocybin commonly say they're aiming for better mood, focus or creativity. Microdosing has the same legal status as any other psilocybin use; there's no legal exemption for small amounts. For a practical guide to how people approach it, see My Mushroom Dispensary's microdosing guide.
What surveys and observational studies found
- Rootman et al., 2021 (Scientific Reports): compared about 4,050 people who microdosed (85% used psilocybin) with 4,653 who didn't. Microdosers with mental health concerns reported lower depression, anxiety and stress.
- Rootman et al., 2022 (Scientific Reports): followed 953 microdosers and 180 non-microdosers for about 30 days and found small to medium improvements in mood and mental health among microdosers.
These studies are large and real-world, but participants knew what they were taking and chose to microdose, so they can't separate the drug's effect from expectation.
What placebo-controlled trials found
| Study | Design | Result |
|---|---|---|
| Szigeti et al., eLife, 2021 | 191 people self-blinded with real or placebo capsules | Everyone improved, including the placebo group; no difference between groups on main outcomes |
| Cavanna et al., Translational Psychiatry, 2022 | 34 people, double-blind psilocybin mushrooms vs placebo | No benefit to wellbeing, creativity or cognition; effects felt stronger mainly by those who guessed correctly |
| Marschall et al., Journal of Psychopharmacology, 2022 | Preregistered crossover trial | No effect on emotion processing, anxiety or depression vs placebo |
| Prochazkova et al., Neuropharmacology, 2026 | Two double-blind trials of psilocybin truffles | No significant effect on cognitive or subjective measures vs placebo; blinding held |
| Prochazkova et al., Neuropharmacology, 2026 | Three trials pooled, 171 people | A small increase in one measure of originality; no other creativity effects |
Two 2026 reviews reached similar conclusions. A meta-analysis of 24 studies and 3,681 healthy adult participants in CNS Drugs found no clear evidence of symptom reduction in randomized trials and suggested observational improvements are likely driven by expectancy. An umbrella review in the Journal of Psychopharmacology found the only significant pooled effect was a small decrease in cognitive control, and that mood benefits weren't replicated under blinding.
The heart-valve question
Psilocin and other psychedelics bind to serotonin 5-HT2B receptors, the same receptors linked to heart-valve damage from some older drugs such as fenfluramine and pergolide. A 2023 review in the Journal of Psychopharmacology concluded the safety margin appears larger than for known valve-damaging drugs, but that frequent, long-term dosing hasn't been properly studied in animals or people, so the risk can't be ruled out.
What's still being studied
- A Phase II trial of psilocybin microdosing for major depression published its protocol in February 2026; results aren't out yet.
- A 2025 RAND survey measured how many Americans microdose psilocybin, LSD and MDMA, giving researchers better national data.
- Effects in specific conditions (ADHD, depression) under blinding remain largely unproven; a 2025 trial of low-dose LSD for ADHD found it no better than placebo.
For the bigger picture on full-dose psilocybin trials, see research and FDA status, and before using any amount, read our safety guide.
Frequently asked questions
Is microdosing psilocybin proven to work?
Not in placebo-controlled trials. People who microdose report benefits in surveys, but when participants don't know whether they're getting psilocybin or placebo, most studies find no clear difference. Expectation appears to explain much of the reported benefit.
Is microdosing safe?
Small amounts carry lower short-term risks than full doses, but the same drug interactions apply, including the danger of combining psilocybin with lithium. The long-term effect of frequent dosing on heart valves through 5-HT2B receptors hasn't been studied enough to rule out risk.
Is microdosing legal?
It has the same legal status as any psilocybin use. It's legal for adults 21+ in Colorado (personal possession and growing) and at licensed service centers in Oregon, and illegal elsewhere. There's no microdose exemption.
Sources
- Rootman et al., adults who microdose psychedelics report health-related motivations and lower levels of anxiety and depression, Scientific Reports, 2021.
- Rootman et al., psilocybin microdosers demonstrate greater observed improvements in mood and mental health, Scientific Reports, 2022.
- Szigeti et al., self-blinding citizen science to explore psychedelic microdosing, eLife, 2021.
- Cavanna et al., microdosing with psilocybin mushrooms: a double-blind placebo-controlled study, Translational Psychiatry, 2022.
- Marschall et al., psilocybin microdosing does not affect emotion-related symptoms, Journal of Psychopharmacology, 2022.
- Prochazkova et al., microdosing psilocybin truffles: two placebo-controlled trials, Neuropharmacology, 2026.
- Prochazkova et al., microdosing and creativity, pooled trials, Neuropharmacology, 2026.
- Meshkat et al., microdosing meta-analysis, CNS Drugs, 2026.
- Özaydın et al., umbrella review of psychedelic microdosing, Journal of Psychopharmacology, 2026.
- Tagen et al., cardiac valvulopathy risk of psychedelics, Journal of Psychopharmacology, 2023.
- Phase II psilocybin microdosing trial protocol, BJPsych Open, February 2026.
- Mueller et al., low-dose LSD for ADHD, JAMA Psychiatry, 2025.
- U.S. psychedelic use and microdosing in 2025, RAND Health Quarterly, 2026.